Notable Insider Filing: George Davis, an Insider in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Sold 5000 shares of the Company

November 23, 2016 - By Nellie Frank

Notable Insider Filing: George Davis, an Insider in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Sold 5000 shares of the Company

George Davis Insider Sell

EVP – General Counsel, George Davis is the Biomarin Pharmaceutical Inc’s insider that unloaded shares of Biomarin Pharmaceutical Inc, 5,000 to be exact. These shares were based on a market stock price per share of $90.4, with the insider trading deal valued at $452,100 USD. This deal was reported on 22-11-2016 and is already filed with the Security and Exchange Commission. The legal report is free at your disposal for review to the public here. George Davis today owns 0.04% of the company’s stock market capitalization with ownership of 70,798 shares. 

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage

Out of 16 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 12 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 75% are positive. $175 is the highest target while $99 is the lowest. The $129.27 average target is 51.32% above today’s ($85.43) stock price. BioMarin Pharmaceutical has been the topic of 36 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating given on Tuesday, January 19 by Wedbush. The firm has “Neutral” rating given on Tuesday, August 25 by Wedbush. Stifel Nicolaus upgraded the stock to “Buy” rating in Tuesday, February 16 report. BMO Capital Markets initiated BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Thursday, April 7 with “Outperform” rating. The firm earned “Overweight” rating on Friday, August 5 by Barclays Capital. Deutsche Bank initiated the shares of BMRN in a report on Thursday, November 3 with “Buy” rating. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Buy” rating given on Tuesday, August 4 by SunTrust. The rating was maintained by Leerink Swann on Tuesday, February 23 with “Outperform”. Piper Jaffray maintained it with “Overweight” rating and $120 target price in Friday, August 5 report. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Neutral” rating given on Monday, November 7 by Piper Jaffray.

Insitutional Activity: The institutional sentiment increased to 1.66 in Q2 2016. Its up 0.38, from 1.28 in 2016Q1. The ratio is positive, as 34 funds sold all BioMarin Pharmaceutical Inc. shares owned while 104 reduced positions. 37 funds bought stakes while 140 increased positions. They now own 153.99 million shares or 5.12% less from 162.30 million shares in 2016Q1.

Amalgamated Financial Bank holds 0.06% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 11,804 shares. Qci Asset Mngmt Inc owns 500 shares or 0.01% of their US portfolio. Pnc Finance Group Inc holds 0% or 47,161 shares in its portfolio. Mycio Wealth Prns Limited Liability Corporation accumulated 719 shares or 0.01% of the stock. The New York-based Healthcor Mgmt L P has invested 3.18% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Moreover, Ci Incorporated has 0.03% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 28,500 shares. Columbus Circle Investors holds 0.14% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 178,355 shares. Fred Alger Management has 1.44 million shares for 0.59% of their US portfolio. Tcw Group Inc accumulated 0.71% or 1.20 million shares. Jane Street Grp Ltd Com last reported 0.01% of its portfolio in the stock. Nippon Life Ins has 0.02% invested in the company for 9,055 shares. Raymond James Assocs holds 0.02% or 61,986 shares in its portfolio. Highbridge Cap Lc last reported 0.05% of its portfolio in the stock. Gulf Savings Bank (Uk) last reported 49,175 shares in the company. Cam A S last reported 0.16% of its portfolio in the stock.

Insider Transactions: Since May 26, 2016, the stock had 0 insider buys, and 21 selling transactions for $73.42 million net activity. 18,467 shares with value of $1.77M were sold by Ajer Jeffrey Robert on Tuesday, September 27. SPIEGELMAN DANIEL K also sold $1.81 million worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Monday, October 31. LAWLIS V BRYAN sold $608,064 worth of stock or 6,400 shares. The insider BIENAIME JEAN JACQUES sold $3.79M. On Monday, August 1 the insider Davis George Eric sold $216,700. Shares for $28,700 were sold by Mueller Brian. The insider FUCHS HENRY J sold $1.43 million.

The stock decreased 2.37% or $2.07 during the last trading session, hitting $85.43. About 1.05M shares traded hands. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has declined 7.13% since April 21, 2016 and is downtrending. It has underperformed by 12.46% the S&P500.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for various diseases and medical conditions. The company has a market cap of $14.45 billion. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. It currently has negative earnings. The Company’s approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

According to Zacks Investment Research, “BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin’s lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.”

More news for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were recently published by: Nasdaq.com, which released: “Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $––.6 ..” on November 11, 2016. Nasdaq.com‘s article titled: “Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $9.8 million ..” and published on November 01, 2016 is yet another important article.

BMRN Company Profile

BioMarin Pharmaceutical Inc. (BioMarin), incorporated on October 25, 1996, develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. The Company’s approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and in other countries. Naglazyme received marketing approval in the United States, the European Union and in other countries. Kuvan was granted marketing approval in the United States and the European Union. Aldurazyme was approved for marketing in the United States, the European Union and in other countries. Firdapse received marketing approval in the European Union.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>